Cancer Family
Glandular Cell Neoplasm
CI-CAN-00000188Explore in graph →
Non-malignant2,823 active trials43 approved drugs426 evidence items
- NCIt
- C7132
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000188Explore in graph →
Clinical trials
10,205 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04121039 | Study of the Apatinib Combine With POF Versus POF in Gastric Cancer | unknown | Phase 2 | 116 | Fujian Cancer HospitalOTHER_GOV | 1 | Oct 9, 2019 | clinicaltrials |
| NCT02926183 | Study of NAC of GA Therapy for Patients With BRPC | unknown | Phase 2 | 60 | Wakayama Medical UniversityOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT01825824 |
| Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma ≤ 5 cm |
| unknown |
| Phase 2 |
| 54 |
| Korea Cancer Center HospitalOTHER |
| 1 |
| Sep 20, 2019 |
| clinicaltrials |
| NCT04094896 | TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer | unknown | Phase 2 | 200 | Guangdong Provincial People's HospitalOTHER | 1 | Sep 19, 2019 | clinicaltrials |
| NCT04095390 | A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer(INPHASE) | unknown | Phase 2 | 60 | Jinming YuOTHER | 1 | Sep 19, 2019 | clinicaltrials |
| NCT04088110 | Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer | unknown | Phase 2 | 77 | Fuzhou General HospitalOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT03592199 | Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib(SuAx) | unknown | Phase 2 | 7 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT04025437 | Neoadjuvant Radiotherapy for HCC Involving Type I PVTT | unknown | Phase 2 / Phase 3 | 214 | Guangxi Medical UniversityOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT04066543 | TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients | unknown | Phase 2 | 40 | Zhejiang Cancer HospitalOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT01682772 | TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate Cancer(TOPARP) | unknown | Phase 2 | 148 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 15, 2019 | clinicaltrials |
| NCT04055038 | Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)(EPITOC) | unknown | Phase 2 / Phase 3 | 164 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT04052152 | Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 9, 2019 | clinicaltrials |
| NCT04049344 | Decitabine Combined With Oxaliplatin in Patients With Advanced Renal Cell Carcinoma | unknown | Phase 2 | 25 | Zhejiang Cancer HospitalOTHER | 1 | Aug 8, 2019 | clinicaltrials |
| NCT04035876 | Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant | unknown | Phase 1 / Phase 2 | 120 | Zhejiang UniversityOTHER | 1 | Jul 29, 2019 | clinicaltrials |
| NCT04034823 | KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer | unknown | Phase 2 | 59 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Jul 26, 2019 | clinicaltrials |
| NCT04033172 | Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )(Pyrotinib) | unknown | Phase 2 | 40 | Chinese Academy of Medical SciencesOTHER | 1 | Jul 25, 2019 | clinicaltrials |
| NCT04031378 | Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer | unknown | Phase 2 | 100 | Fundacao ChampalimaudOTHER | 1 | Jul 24, 2019 | clinicaltrials |
| NCT04014101 | SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma(SHR-1210) | unknown | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 11, 2019 | clinicaltrials |
| NCT03990103 | S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites | unknown | Phase 2 | 66 | China Medical University, ChinaOTHER | 1 | Jun 19, 2019 | clinicaltrials |
| NCT01047969 | Avoiding Surgery in Rectal Cancer After Pre-Operative Therapy | unknown | Phase 2 | 99 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 13, 2019 | clinicaltrials |
| NCT01372579 | Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients | unknown | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Jun 7, 2019 | clinicaltrials |
| NCT03966118 | Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma(AIO-STO-0218) | unknown | Phase 2 | 59 | P. C. Thuss-PatienceOTHER | 1 | Jun 3, 2019 | clinicaltrials |
| NCT03634332 | Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC | unknown | Phase 2 | 35 | Pancreatic Cancer Research TeamOTHER | 1 | May 7, 2019 | clinicaltrials |
| NCT03932526 | Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer | unknown | Phase 2 | 184 | Liaoning Cancer Hospital & InstituteOTHER | 0 | Apr 30, 2019 | clinicaltrials |
| NCT03919253 | Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study | unknown | Phase 2 | 80 | Hebei Medical University Fourth HospitalOTHER | 0 | Apr 18, 2019 | clinicaltrials |
| NCT03812770 | Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC | unknown | Phase 2 | 150 | Sun Yat-sen UniversityOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT03910712 | Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC(Pyrotinib) | unknown | Phase 2 | 250 | Peking Union Medical College HospitalOTHER | 0 | Apr 10, 2019 | clinicaltrials |
| NCT03905317 | Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene | unknown | Phase 2 | 66 | Sun Yat-sen UniversityOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT03881878 | TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery | unknown | Phase 1 / Phase 2 | 67 | Samsung Medical CenterOTHER | 1 | Mar 21, 2019 | clinicaltrials |
| NCT03857815 | Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients With Hepatocellular Carcinoma | unknown | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT02007148 | MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer(MICADO) | unknown | Phase 2 | 51 | International Group of Endovascular OncologyOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT03851887 | The Efficacy of Transarterial Chemoinfusion (TAI) Combine Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 33 | Sun Yat-sen UniversityOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT03851939 | The Efficacy of Transarterial Chemoinfusion (TAI) Combine Toripalimab in Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 65 | Sun Yat-sen UniversityOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT03839550 | Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection | unknown | Phase 2 | 200 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT03837301 | Non-exposure Simple Suturing EFTR (NESS-EFTR) With Laparoscopic Sentinel Lymph Node Navigation for EGC (Senorita3-phase 2) | unknown | Phase 2 | 88 | National Cancer Center, KoreaOTHER_GOV | 1 | Feb 12, 2019 | clinicaltrials |
| NCT03812783 | HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC | unknown | Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT03793725 | A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC(HZ-T-PD1-APA) | unknown | Phase 2 | 30 | Yanqiao ZhangOTHER | 0 | Jan 4, 2019 | clinicaltrials |
| NCT03116945 | Novel Gallium Imaging in Hepatocellular Carcinoma | unknown | Phase 2 | 18 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT02759601 | Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)(CHR-2845) | unknown | Phase 1 / Phase 2 | 69 | Queen Mary University of LondonOTHER | 1 | Dec 20, 2018 | clinicaltrials |
| NCT03775928 | Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer | unknown | Phase 2 | 80 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 14, 2018 | clinicaltrials |
| NCT03732547 | Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 60 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 16, 2018 | clinicaltrials |
| NCT03692689 | Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer | unknown | Phase 2 | 30 | Sinocelltech Ltd.INDUSTRY | 1 | Oct 2, 2018 | clinicaltrials |
| NCT03684863 | Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy | unknown | Phase 2 | 200 | Shandong Cancer Hospital and InstituteOTHER | 0 | Sep 26, 2018 | clinicaltrials |
| NCT01037049 | Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks | unknown | Phase 2 | 237 | Royal Marsden NHS Foundation TrustOTHER | 4 | Sep 17, 2018 | clinicaltrials |
| NCT03636685 | Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC | unknown | Phase 1 / Phase 2 | 60 | Chinese Academy of Medical SciencesOTHER | 0 | Aug 17, 2018 | clinicaltrials |
| NCT02919878 | Neo-adjuvant Chemoradiotherapy Using Infusional Gemcitabine Followed by Surgery for Locally Advanced Rectal Cancer | unknown | Phase 2 | 25 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Aug 13, 2018 | clinicaltrials |
| NCT02919371 | Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA) | unknown | Phase 1 / Phase 2 | 77 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT02525068 | A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC(RE-AKT) | unknown | Phase 2 | 136 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 8, 2018 | clinicaltrials |
| NCT03591666 | A Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas | unknown | Phase 2 | 51 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jul 19, 2018 | clinicaltrials |
| NCT03341845 | Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC | unknown | Phase 2 | 40 | The Netherlands Cancer InstituteOTHER | 1 | May 21, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Oct 9, 2019source: clinicaltrials